Traduction de «for which » (Français → Néerlandais) :

Combinaison therapy for neuropathic pain – Which drugs, which combinaison, which patients?
Combination therapy for neuropathic pain – Which drugs, which combination, which patients?

It is therefore closely related to appropriateness, which can be defined as “the degree to which provided healthcare is relevant to the clinical
It is therefore closely related to appropriateness, which can be defined as “the degree to which provided healthcare is relevant to the clinical needs, given the current best evidence and the provider’s experience”. The link between effectiveness and appropriateness reflects the link

If participation in health care decisions is seen as an end in itself (empowerment perspective), it follows that decisions made through a participatory process are valuable and legitimate, because they emanate from a participatory process which is valued in itself, regardless
If participation in health care decisions is seen as an end in itself (empowerment perspective), it follows that decisions made through a participatory process are valuable and legitimate, because they

Anonyme.: Which statin, what dose?
Anoniem.: Which statin, what dose?

The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than lowintensity, particularly with nicotine gum, although this was of no significance.
The absolute probability of not smoking at 6 to 12 months was greater in trials which provided high-intensity additional support, rather than low-intensity, particularly with nicotine gum, although this was of no significance.

The only adverse events which occur significantly more with Bupropion slow release than with placebo are insomnia and dry mouth 2; 3 .
The only adverse events which occur significantly more with bupropion slow release than with placebo are insomnia and dry mouth 2; 3 .

Les termes et conditions repris sur le registre du site de la Commission européenne mentionnent que “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.
De termen en voorwaarden opgenomen in het register op de website van de Europese Commissie vermelden “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.

PCAS in asymptomatic and symptomatic patients show 30 day rates of stroke and death of 1.8% (N=896, 63% symptomatic) 35 , 2.2% (K-M estimate, N=143 of which 37.1% symptomatic) 39, 3.2% (N=2111 symptomatic patients)34, 2.5% (N=2110 asymptomatic patients) 34, 5.2% (N=97 symptomatic)36, 11.3%(N=53, 57% symptomatic > 75 year old)32, 3.8% (N=213 symptomatic)33, 3.2% (N=602 asymptomatic)33, 2% (N=86> 79 years old)33, 3.7% (N=159 29.9% symptomatic) 28 .
PCAS in asymptomatic and symptomatic patients show 30 day rates of stroke and death of 1.8% (N=896, 63% symptomatic)35, 2.2% (K-M estimate, N=143 of which 37.1% symptomatic) 39, 3.2% (N=2111 symptomatic patients)34, 2.5% (N=2110 asymptomatic patients) 34, 5.2% (N=97 symptomatic)36, 11.3%(N=53, 57% symptomatic > 75 year old)32, 3.8% (N=213 symptomatic)33, 3.2% (N=602 asymptomatic)33, 2% (N=86> 79 years old)33, 3.7% (N=159 29.9% symptomatic)28.

Older trials showed poor outcomes, and two randomised trials of carotid stenting were stopped early after these poor outcomes in stented patients.16 These early trials used techniques which have now been superseded, but the safety of endovascular treatment remains as yet insufficiently known.
Older trials showed poor outcomes, and two randomised trials of carotid stenting were stopped early after these poor outcomes in stented patients. 16 These early trials used techniques which have now been superseded, but the safety of endovascular treatment remains as yet insufficiently known.

Figure 2. 1: Health states for which utilities are neededd (reflection process) .Figure 2. 2: Percentage change in utilities .Figure 3. 1: Comparison of the two cohorts with and without a screening program .Figure 3. 2: Compartments in the two cohorts and the transitions between them .
Figure 2. 1: Health states for which utilities are neededd (reflection process) . Figure 2.2: Percentage change in utilities .